ROSIGLITAZONE EFFCT ON ADIPCYTE-DERIVD CYTOKINES IN NONDIABTC PTS W/METABLC SYND

罗格列酮对非NDIABTC PTS W/METABLC SYND 中脂肪细胞衍生细胞因子的影响

• 批准号: 7719460
• 负责人: CHRISTINA L AQUILANTE
• 金额: $ 0.22万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719460
• 关键词: Adipocytes; Cardiovascular Diseases; Caring; Collection; Computer Retrieval of Information on Scientific Projects Database; Development; Disease Progression; Funding; Future; Grant; Health; Institution; Insulin; Metabolic syndrome; Non-Insulin-Dependent Diabetes Mellitus; Persons; Pharmaceutical Preparations; Population; Proteins; Purpose; Rate; Research; Research Personnel; Resources; Risk; Source; Standards of Weights and Measures; United States; United States National Institutes of Health; cytokine; improved; insulin sensitizing drugs; rosiglitazone

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine if rosiglitazone, an 'insulin sensitizer', will favorably alter fat cell proteins in people with the metabolic syndrome. The metabolic syndrome is a collection of health risks that increase a person's chance for the future development of type 2 diabetes and cardiovascular disease. Because the metabolic syndrome is increasing at alarming rates in the United States, identification of alternative ways to alter disease progression in this population is essential. Rosiglitazone may be helpful in altering the amount of proteins made by the fat cells. This may improve the body's ability to use insulin and impact some of the parts of the metabolic syndrome. Currently, use of medications, like rosiglitazone, is not standard of care in people who have the metabolic syndrome. Our study is an early step to see if rosiglitazone will be beneficial in people who have the metabolic syndrome.

这个子项目是众多研究子项目之一